Takeda and Amylin to develop and commercialize pharmaceutical products for obesity Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Organization Limited announced today they have entered into a worldwide distinctive license, advancement and commercialization contract to co-develop and commercialize pharmaceutical products for the treating obesity and related indications tadapox patent . The agreement includes products to be developed from Amylin’s pipeline, including pramlintide/metreleptin and davalintide, which are compounds presently in phase 2 advancement for treatment of weight problems.
We are very happy to announce this essential collaboration with Anacor, stated Jonah Shacknai, Chairman and CEO of Medicis. Anacor and its scientists are well respected in the scientific community, and Medicis can be proud to be among various other significant organizations who’ve partnered with them to explore the pharmaceutical development of the Anacor boron chemistry system. We will collectively be working hard to accomplish breakthroughs with this proprietary technology in the treating acne. We’ve demonstrated that boron-structured chemistry is successful in creating novel little molecule therapeutics, and we are excited to work with Medicis to apply this technology to the development of a distinctive, patented treatment for acne, said David Perry, Anacor’s Chief Executive Officer.